title: Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12.
abstract: Dendritic cells (DC) enhanced the immunogenicity of recombinant vaccinia viruses (rVV) expressing the E7 protein of HPV16, a tumor-associated antigen (TAA). Immunization with DC transduced by rVV generated from strain Praha or MVA induced better protection against the growth of transplanted TC-1 tumors in C57Bl/6 mice than did immunization with either of these rVVs administered alone by the same route. Interestingly, DC transduced with a double recombinant vaccinia virus expressing E7 protein together with the Th1-polarizing cytokine IL12, which has been shown to enhance the cellular response in several other systems, induced lower anti-tumor immunity than DC transduced with rVV expressing E7 protein alone. The inhibitory effect mediated by IL12 on immunization with rVV-infected DC was dose-dependent and was observed after immunization with DC transduced with IL12-expressing rVV even at low multiplicity.
authors.affiliation: Institute of Hematology and Blood Transfusion, Department of Experimental Virology, 128 20 Prague 2, Czech Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Mackova
authors.forename: Luda
authors.initials: L
authors.lastname: Kutinova
authors.forename: Petr
authors.initials: P
authors.lastname: Hainz
authors.forename: Jitka
authors.initials: J
authors.lastname: Krystofova
authors.forename: Vojtech
authors.initials: V
authors.lastname: Sroller
authors.forename: Pavel
authors.initials: P
authors.lastname: Otahal
authors.forename: Pavel
authors.initials: P
authors.lastname: Gabriel
authors.forename: Sarka
authors.initials: S
authors.lastname: Nemeckova
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D017951:Antigen Presentation; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007114:Immunization; D007167:Immunotherapy; D018664:Interleukin-12 / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy* / Q000821:virology; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D027383:Papillomaviridae / Q000502:physiology; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000235:genetics / Q000276:immunology / Q000628:therapy; D015996:Survival Rate; D018417:Th1 Cells / Q000276:immunology; D014161:Transduction, Genetic; D014616:Vaccinia virus / Q000235:genetics*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; D018664:Interleukin-12